Know Cancer

forgot password

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

Phase 3
29 Years
Open (Enrolling)

Thank you

Trial Information

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults



- Compare the event-free survival (EFS) and overall survival (OS) of young patients with
newly diagnosed acute myeloid leukemia (AML) treated with conventional combination
chemotherapy with vs without gemtuzumab ozogamicin (GMTZ).


- Compare the remission induction rates after two courses of therapy in these patients.

- Compare disease-free survival and OS in patients who are eligible for an HLA-matched
family donor (MFD) stem cell transplant (SCT) by virtue of their risk classification,
with patients assigned to MFD SCT if a MFD is available, or to chemotherapy if a MFD is
not available.

- Determine the outcome of patients with Down syndrome who are 4 years of age or older at
diagnosis and treated with conventional combination chemotherapy without GMTZ.

- Compare the EFS and OS of patients with de novo AML treated with conventional
combination chemotherapy with vs without GMTZ censoring MFD SCT recipients.

- Determine the prevalence and prognostic significance of molecular abnormalities of KIT,
CEBPα and MLL-PTD genes in these patients.

- Determine the leukemic involvement of hematopoietic early progenitor and its role in
defining response to therapy.

- Assess the ability of a second-generation flow cytometric assay to predict patients at
high risk for relapse during periods of clinical remission.

- Examine whether GMTZ significantly improves EFS and OS in patients with higher CD33

- Examine whether GMTZ significantly improves complete remission, EFS, and OS in each of
the cytogenetic risk groups (high-, intermediate-, and low-risk) identified in prior
Medical Research Council trials.

- Utilize fluorescence in situ hybridization (FISH) analysis to identify variant patterns
among subgroups of patients who demonstrate the same G-banded chromosomal abnormality
(e.g., inv[16]/t[16;16], t[8;21], 11q23 abnormality) and determine whether these
variant patterns account for the heterogeneity of responses to therapy.

- Examine the impact of complex karyotypes (≥ 3, ≥ 4, and ≥ 5 abnormalities) on OS and
EFS in intermediate-risk patients for whom no high-risk or low-risk cytogenetic
abnormalities exist.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
relapse risk (high vs intermediate vs low). Patients are randomized to 1 of 2 treatment
arms. Patients with Down syndrome are nonrandomly assigned to arm I (but do not undergo
allogeneic stem cell transplant [SCT]).

- Arm I (standard therapy):

- Induction 1: Patients receive cytarabine IT at the time of diagnosis or on day 1*.
Patients also receive cytarabine IV on days 1-10, daunorubicin hydrochloride IV
over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After
3 weeks of rest, all patients (regardless of remission status) proceed to
induction 2.

NOTE: *Patients with CNS disease receive cytarabine IT twice weekly until the cerebrospinal
fluid is clear, followed by two additional IT treatments. Patients with refractory CNS
leukemia after 6 doses of IT treatment are removed from the study.

- Induction 2: Patients receive cytarabine IT on day 1, cytarabine IV on days 1-8,
daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4
hours on days 1-5. After 3 weeks of rest, patients in complete remission (CR) proceed
to intensification 1. Patients with refractory disease are removed from protocol

- Intensification 1: Patients receive cytarabine IT on day 1, high-dose cytarabine IV
over 1 hour on days 1-5, and etoposide IV over 1 hour on days 1-5. After 3 weeks of
rest, patients in remission proceed to intensification 2, followed by intensification
3. Patients in remission proceed to allogeneic SCT 2-8 weeks after blood counts
recover. Patients with high-risk disease with an alternative donor proceed to
intensification 2 and 3, followed by allogeneic SCT. Patients not in remission are
removed from protocol therapy.

- Intensification 2: Patients receive cytarabine IT on day 1, high-dose cytarabine IV
over 2 hours on days 1-4, and mitoxantrone hydrochloride IV over 1 hour on days 3-6.
After 3 weeks of rest, patients proceed to intensification 3.

- Intensification 3: Patients receive high-dose cytarabine IV over 3 hours on days 1, 2,
8, and 9 and asparaginase intramuscularly on days 2 and 9.

- Arm II:

- Induction 1: Patients receive treatment as in induction 1 of arm I. Patients also
receive gemtuzumab ozogamicin (GMTZ) IV over 2 hours on day 6.

- Induction 2: Patients receive treatment as in induction 2 of arm I.

- Intensification 1: Patients receive treatment as in intensification 1 of arm I.

- Intensification 2: Patients receive treatment as in intensification 2 of arm I.
Patients also receive GMTZ IV over 2 hours on day 7.

- Intensification 3: Patients receive treatment as in intensification 3 of arm I.

- Allogeneic SCT (for patients with intermediate- or high-risk disease):

- MFD: Patients receive a conditioning regimen comprising busulfan IV over 2 hours every
6 hours on days -9 to -6 and cyclophosphamide IV over 1 hour on days -5 to -2. Patients
undergo allogeneic SCT on day 0. Patients receive cyclosporine IV or orally twice daily
on days -1 to 180 and methotrexate IV on days 1, 3, 6, and 11. Patients receive
graft-vs-host disease (GVHD) prophylaxis comprising cyclosporine IV over 1-4 hours or
orally twice daily on days -1 to 180 and methotrexate IV on days 1, 3, 6, and 11.

- Matched alternative donor: Patients receive a conditioning regimen comprising busulfan
and cyclophosphamide as above. Patients also receive antithymocyte globulin IV over 6-8
hours on days -3 to -1. Patients then undergo allogeneic SCT and receive GVHD
prophylaxis as above.

After completion of study treatment, patients are followed periodically for 3 years and then
annually thereafter.

PROJECTED ACCRUAL: A total of 1,012 patients will be accrued for this study.

Inclusion Criteria


- Newly diagnosed acute myeloid leukemia (AML)

- Meets customary criteria for AML with ≥ 20% bone marrow blasts (by WHO

- Patients with < 20% bone marrow blasts and cytopenia or myelodysplastic
syndromes (e.g., chronic myelomonocytic leukemia, refractory anemia [RA],
RA with excess blasts, RA with ringed sideroblasts) are eligible provided 1
of the following criteria is met:

- Karyotypic abnormality characteristic of de novo AML
(t[8;21][q22;q22], inv[16][p13q22], t[16;16][p13;q22], or 11q23

- Unequivocal presence of megakaryoblasts (by WHO classification)

- Isolated myeloid sarcoma (i.e., myeloblastoma or chloroma) allowed regardless of
bone marrow results

- Infants < 1 month of age with progressive disease* are eligible NOTE: *Infants < 1
month of age with AML may be given supportive care until it is clear that the
leukemia is not regressing (i.e., the disappearance of peripheral blasts and the
normalization of peripheral blood counts)

- Patients with Down syndrome ≥ 4 years of age are eligible

- No juvenile myelomonocytic leukemia

- No Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone
marrow failure syndrome

- No promyelocytic leukemia (M3)

- No secondary or treatment-related AML

- Matched family donor criteria (for patients with intermediate-risk or high-risk

- HLA-A, -B, -C, and -DRB1, identical or 1 antigen or allele mismatched by
molecular high resolution technique

- All available first-degree family members (parents and siblings) must be HLA

- No syngeneic donors

- Matched alternative donor criteria (for patients with high-risk disease):

- HLA-A, -B, -C, and -DRB1, identical or 1 antigen or allele mismatched donor

- HLA-A, -B, and -DRB1 4 of 6 antigen matched unrelated cord blood donor

- Mismatched family member donor with ≥ 1 haplotype match or 5 of 6 antigen
phenotypic match


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception


- No prior chemotherapy, radiation therapy, or any antileukemic therapy

- Topical or inhalation steroids for other conditions allowed

- Intrathecal cytarabine given at diagnosis allowed

- No other prior treatment for AML

- No concurrent peripheral blood stem cell transplantation in patients with matched
family donor

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Event-free survival

Outcome Description:

The Kaplan-Meier method will be used to calculate estimates of EFS. The log-rank test will be used to compare survival between treatment groups. Analysis of EFS of Down syndrome patients will be performed separately. Monitoring for efficacy of GMTZ with respect to OS and EFS will utilize monitoring based on the Lan-DeMets criterion with α-spending function αt^2 (truncated at 3 standard deviations) and 2.5% type I error.

Outcome Time Frame:

Time from study entry to time of induction failure, relapse, or death

Safety Issue:


Principal Investigator

Alan S. Gamis, MD, MPH

Investigator Role:

Study Chair

Investigator Affiliation:

Children's Mercy Hospital


United States: Federal Government

Study ID:




Start Date:

August 2006

Completion Date:

Related Keywords:

  • Leukemia
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • untreated adult acute myeloid leukemia
  • untreated childhood acute myeloid leukemia and other myeloid malignancies
  • adult acute basophilic leukemia
  • adult acute eosinophilic leukemia
  • adult acute minimally differentiated myeloid leukemia (M0)
  • adult acute myeloblastic leukemia without maturation (M1)
  • adult acute myeloblastic leukemia with maturation (M2)
  • adult acute myelomonocytic leukemia (M4)
  • adult acute monoblastic leukemia (M5a)
  • adult acute monocytic leukemia (M5b)
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • adult acute megakaryoblastic leukemia (M7)
  • childhood acute basophilic leukemia
  • childhood acute eosinophilic leukemia
  • childhood acute minimally differentiated myeloid leukemia (M0)
  • childhood acute myeloblastic leukemia without maturation (M1)
  • childhood acute myeloblastic leukemia with maturation (M2)
  • childhood acute myelomonocytic leukemia (M4)
  • childhood acute monocytic leukemia (M5b)
  • childhood acute monoblastic leukemia (M5a)
  • childhood acute erythroleukemia (M6)
  • childhood acute megakaryocytic leukemia (M7)
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



Roswell Park Cancer InstituteBuffalo, New York  14263
Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania  19104
Mayo Clinic Cancer CenterRochester, Minnesota  55905
Cardinal Bernardin Cancer Center at Loyola University Medical CenterMaywood, Illinois  60153-5500
Walter Reed Army Medical CenterWashington, District of Columbia  20307-5000
University of Chicago Cancer Research CenterChicago, Illinois  60637
Barbara Ann Karmanos Cancer InstituteDetroit, Michigan  48201
Duke Comprehensive Cancer CenterDurham, North Carolina  27710
Tripler Army Medical CenterHonolulu, Hawaii  96859-5000
Hurley Medical CenterFlint, Michigan  48503
Medical City Dallas HospitalDallas, Texas  75230
University of Texas Health Science Center at San AntonioSan Antonio, Texas  78284-7811
CCOP - KalamazooKalamazoo, Michigan  49007-3731
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health CenterFarmington, Connecticut  06360-2875
Baystate Regional Cancer Program at D'Amour Center for Cancer CareSpringfield, Massachusetts  01199
Van Elslander Cancer Center at St. John Hospital and Medical CenterGrosse Pointe Woods, Michigan  48236
CCOP - MeritCare HospitalFargo, North Dakota  58122
Penn State Cancer Institute at Milton S. Hershey Medical CenterHershey, Pennsylvania  17033-0850
Sanford Cancer Center at Sanford USD Medical CenterSioux Falls, South Dakota  57117-5039
Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
University of Wisconsin Paul P. Carbone Comprehensive Cancer CenterMadison, Wisconsin  53792-6164
Marshfield Clinic - Marshfield CenterMarshfield, Wisconsin  54449
Newark Beth Israel Medical CenterNewark, New Jersey  07112
Holden Comprehensive Cancer Center at University of IowaIowa City, Iowa  52242-1002
UMASS Memorial Cancer Center - University CampusWorcester, Massachusetts  01605-2982
Ellis Fischel Cancer Center at University of Missouri - ColumbiaColumbia, Missouri  65203
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire  03756-0002
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillChapel Hill, North Carolina  27599-7570
CCOP - Scott and White HospitalTemple, Texas  76508
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland  21231-2410
Cancer Research Center of HawaiiHonolulu, Hawaii  96813
Cleveland Clinic Taussig Cancer CenterCleveland, Ohio  44195
Sutter Cancer CenterSacramento, California  95816
Children's Hospital of Orange CountyOrange, California  92668
Children's National Medical CenterWashington, District of Columbia  20010-2970
Children's Mercy HospitalKansas City, Missouri  64108
St. Joseph's Hospital and Medical CenterPaterson, New Jersey  07503
Children's Hospital of PittsburghPittsburgh, Pennsylvania  15213
Children's Hospital and Regional Medical Center - SeattleSeattle, Washington  98105
University of California Davis Cancer CenterSacramento, California  95817
Nemours Children's ClinicJacksonville, Florida  32207
Miami Children's HospitalMiami, Florida  33155-4069
All Children's HospitalSt. Petersburg, Florida  33701
Children's Memorial Hospital - ChicagoChicago, Illinois  60614
Children's Hospital of New OrleansNew Orleans, Louisiana  70118
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer InstituteBoston, Massachusetts  02115
Cardinal Glennon Children's HospitalSaint Louis, Missouri  63104
Schneider Children's HospitalNew Hyde Park, New York  11042
St. Christopher's Hospital for ChildrenPhiladelphia, Pennsylvania  19134-1095
Driscoll Children's HospitalCorpus Christi, Texas  78466
Cook Children's Medical Center - Fort WorthFort Worth, Texas  76104
Inova Fairfax HospitalFalls Church, Virginia  22042-3300
City of Hope Comprehensive Cancer CenterDuarte, California  91010
Fletcher Allen Health Care - University Health Center CampusBurlington, Vermont  05401
Phoenix Children's HospitalPhoenix, Arizona  85016-7710
Southern California Permanente Medical GroupDowney, California  90242
Children's Hospital Central CaliforniaMadera, California  93638-8762
Kosair Children's HospitalLouisville, Kentucky  40202-3830
Brooklyn Hospital CenterBrooklyn, New York  11201
Children's Medical Center - DaytonDayton, Ohio  45404
Palmetto Health South Carolina Cancer CenterColumbia, South Carolina  29203
East Tennessee Children's HospitalKnoxville, Tennessee  37901
Covenant Children's HospitalLubbock, Texas  79410
Children's Hospital of the King's DaughtersNorfolk, Virginia  23507
Midwest Children's Cancer Center at Children's Hospital of WisconsinMilwaukee, Wisconsin  53226
Arizona Cancer Center at University of Arizona Health Sciences CenterTucson, Arizona  85724
Arkansas Cancer Research Center at University of Arkansas for Medical SciencesLittle Rock, Arkansas  72205
Kansas Masonic Cancer Research Institute at the University of Kansas Medical CenterKansas City, Kansas  66160-7353
Blumenthal Cancer Center at Carolinas Medical CenterCharlotte, North Carolina  28232-2861
Overlook HospitalSummit, New Jersey  07902-0220
Winthrop University HospitalMineola, New York  11501
Loma Linda University Cancer Institute at Loma Linda University Medical CenterLoma Linda, California  92354
Jonathan Jaques Children's Cancer Center at Miller Children's HospitalLong Beach, California  90801
Kaiser Permanente Medical Center - OaklandSacramento, California  95825
Santa Barbara Cottage Children's HospitalSanta Barbara, California  93105
Yale Cancer CenterNew Haven, Connecticut  06520-8028
Lee Cancer Care of Lee Memorial Health SystemFort Myers, Florida  33901
Broward General Medical Center Cancer CenterFt. Lauderdale, Florida  33316
University of Florida Shands Cancer CenterGainesville, Florida  32610-0232
Baptist-South Miami Regional Cancer ProgramMiami, Florida  33176
Nemours Children's Clinic - OrlandoOrlando, Florida  32806
Florida Hospital Cancer Institute at Florida Hospital OrlandoOrlando, Florida  32803-1273
Sacred Heart Cancer Center at Sacred Heart HospitalPensacola, Florida  32504
St. Joseph's Cancer Institute at St. Joseph's HospitalTampa, Florida  33607
Kaplan Cancer Center at St. Mary's Medical CenterWest Palm Beach, Florida  33407
Winship Cancer Institute of Emory UniversityAtlanta, Georgia  30322
Advocate Christ Medical CenterOak Lawn, Illinois  60453
St. Vincent Indianapolis HospitalIndianapolis, Indiana  46260
Blank Children's HospitalDes Moines, Iowa  50309
Alvin and Lois Lapidus Cancer Institute at Sinai HospitalBaltimore, Maryland  21215
Floating Hospital for Children at Tufts - New England Medical CenterBoston, Massachusetts  02111
Breslin Cancer Center at Ingham Regional Medical CenterLansing, Michigan  48910
Hackensack University Medical Center Cancer CenterHackensack, New Jersey  07601
Albert Einstein Cancer Center at Albert Einstein College of MedicineBronx, New York  10461
NYU Cancer Institute at New York University Medical CenterNew York, New York  10016
Mount Sinai Medical CenterNew York, New York  10029
Stony Brook University Cancer CenterStony Brook, New York  11794-8174
SUNY Upstate Medical University HospitalSyracuse, New York  13210
Mission Hospitals - Memorial CampusAsheville, North Carolina  28801
Presbyterian Cancer Center at Presbyterian HospitalCharlotte, North Carolina  28233-3549
Wake Forest University Comprehensive Cancer CenterWinston-Salem, North Carolina  27157-1096
Cincinnati Children's Hospital Medical CenterCincinnati, Ohio  45229-3039
Rainbow Babies and Children's HospitalCleveland, Ohio  44106-5000
Medical University of Ohio Cancer CenterToledo, Ohio  43614
Toledo HospitalToledo, Ohio  43606
Rhode Island Hospital Comprehensive Cancer CenterProvidence, Rhode Island  02903
Hollings Cancer Center at Medical University of South CarolinaCharleston, South Carolina  29425
Texas Tech University Health Sciences Center School of Medicine - AmarilloAmarillo, Texas  79106
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - DallasDallas, Texas  75390
Baylor University Medical Center - HoustonHouston, Texas  77030-2399
Methodist Children's Hospital of South TexasSan Antonio, Texas  78229-3993
Primary Children's Medical CenterSalt Lake City, Utah  84113-1100
Naval Medical Center - PortsmouthPortsmouth, Virginia  23708-2197
Providence Cancer Center at Sacred Heart Medical CenterSpokane, Washington  99220-2555
St. Vincent Hospital Regional Cancer CenterGreen Bay, Wisconsin  54307-3508
James P. Wilmot Cancer Center at University of Rochester Medical CenterRochester, New York  14642
Greenebaum Cancer Center at University of Maryland Medical CenterBaltimore, Maryland  21201
UNMC Eppley Cancer Center at the University of Nebraska Medical CenterOmaha, Nebraska  68198-7680
Memorial Cancer Institute at Memorial Regional HospitalHollywood, Florida  33021
New York Weill Cornell Cancer Center at Cornell UniversityNew York, New York  10021
University of South Alabama Mitchell Cancer InstituteMobile, Alabama  36604
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical CenterLos Angeles, California  90048-1865
Jonsson Comprehensive Cancer Center at UCLALos Angeles, California  90095-1781
Childrens Hospital Los AngelesLos Angeles, California  90027
Children's Hospital and Research Center OaklandOakland, California  94609
Rady Children's Hospital - San DiegoSan Diego, California  92123-4282
UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California  94115
Children's Hospital Center for Cancer and Blood DisordersAurora, Colorado  80045
Alfred I. duPont Hospital for ChildrenWilmington, Delaware  19803
M.D. Anderson Cancer Center at OrlandoOrlando, Florida  32806
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston CampusAtlanta, Georgia  30322
MBCCOP - Medical College of Georgia Cancer CenterAugusta, Georgia  30912-3730
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical CenterSavannah, Georgia  31403-3089
Mountain States Tumor Institute at St. Luke's Regional Medical CenterBoise, Idaho  83712-6297
University of Illinois Cancer CenterChicago, Illinois  60612-7243
Keyser Family Cancer Center at Advocate Hope Children's HospitalOak Lawn, Illinois  60453
Advocate Lutheran General Cancer Care CenterPark Ridge, Illinois  60068-1174
Simmons Cooper Cancer InstituteSpringfield, Illinois  62794-9677
Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana  46202-5289
Lucille P. Markey Cancer Center at University of KentuckyLexington, Kentucky  40536-0093
Tulane Cancer Center Office of Clinical ResearchAlexandria, Louisiana  71315-3198
CancerCare of Maine at Eastern Maine Medical CenterBangor, Maine  04401
Maine Children's Cancer Program at Barbara Bush Children's HospitalScarborough, Maine  04074-9308
C.S. Mott Children's Hospital at University of Michigan Medical CenterAnn Arbor, Michigan  48109-0286
Butterworth Hospital at Spectrum HealthGrand Rapids, Michigan  49503-2560
Masonic Cancer Center at University of MinnesotaMinneapolis, Minnesota  55455
Children's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis, Minnesota  55404
University of Mississippi Cancer ClinicJackson, Mississippi  39216-4505
Siteman Cancer Center at Barnes-Jewish Hospital - Saint LouisSt. Louis, Missouri  63110
Children's HospitalOmaha, Nebraska  68114-4113
CCOP - Nevada Cancer Research FoundationLas Vegas, Nevada  89109-2306
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical SchoolNew Brunswick, New Jersey  08903
University of New Mexico Cancer CenterAlbuquerque, New Mexico  87131-5636
Albany Medical Center HospitalAlbany, New York  12208-3419
Herbert Irving Comprehensive Cancer Center at Columbia University Medical CenterNew York, New York  10032
Akron Children's HospitalAkron, Ohio  44308-1062
Nationwide Children's HospitalColumbus, Ohio  43205-2696
Oklahoma University Cancer InstituteOklahoma City, Oklahoma  73104
Knight Cancer Institute at Oregon Health and Science UniversityPortland, Oregon  97239-3098
Legacy Emanuel Hospital and Health Center and Children's HospitalPortland, Oregon  97227
Geisinger Cancer Institute at Geisinger HealthDanville, Pennsylvania  17822-0001
Penn State Children's HospitalHershey, Pennsylvania  17033-0850
Dell Children's Medical Center of Central TexasAustin, Texas  78723
Virginia Commonwealth University Massey Cancer CenterRichmond, Virginia  23298-0037
Carilion Medical Center for Children at Roanoke Community HospitalRoanoke, Virginia  24014
Madigan Army Medical Center - TacomaTacoma, Washington  98431
Mary Bridge Children's Hospital and Health Center - TacomaTacoma, Washington  98405
West Virginia University Health Sciences Center - CharlestonCharleston, West Virginia  25302
University of Virginia Cancer CenterCharlottesville, Virginia  22908
Massachusetts General HospitalBoston, Massachusetts  02114-2617
UAB Comprehensive Cancer CenterBirmingham, Alabama  35294
University of Miami Sylvester Comprehensive Cancer Center - MiamiMiami, Florida  33136
Leo W. Jenkins Cancer Center at ECU Medical SchoolGreenville, North Carolina  27834
Lehigh Valley Hospital - MuhlenbergBethlehem, Pennsylvania  18017
Greenville Hospital Cancer CenterGreenville, South Carolina  29605
T.C. Thompson Children's HospitalChattanooga, Tennessee  37403
Banner Desert Medical CenterMesa, Arizona  85202